SIGA Technologies, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011; filed March 1, 2012. SIGA develops antiviral drugs for biodefense and other serious viral threats. Its lead product is ST-246, an investigational smallpox antiviral, and its business depends heavily on U.S. government contracts and grants.
Financial performance and position
| Metric | FY2011 | FY2010 |
|---|---|---|
| Revenue | $12.7 million | $19.2 million |
| Operating expenses | $44.1 million | $31.9 million |
| Operating loss | $31.4 million | $12.7 million |
| Net income (loss) | $13.6 million | ($28.2 million) |
| Operating cash flow | $25.6 million | ($10.8 million) |
| Cash and short-term investments at year-end | $49.3 million | $21.3 million |
| Total assets | $90.4 million | $27.0 million |
| Total liabilities | $48.7 million | $15.0 million |
Revenue fell 34%, mainly because federal development awards concluded. SG&A rose to $23.9 million from $8.1 million, including substantially higher stock-based compensation and a legal contingency; R&D declined 19% to $18.4 million. The $13.6 million net profit did not reflect operating profitability: it included a $36.0 million income-tax benefit, primarily from releasing part of the deferred-tax valuation allowance, and an $8.9 million noncash gain from lower warrant fair value. Basic EPS was $0.27 and diluted EPS $0.09. The filing reports no conventional debt balance; year-end current liabilities were $6.9 million, alongside $41.0 million of deferred revenue.
Operating cash flow was boosted principally by $41.0 million in BARDA advance payments. Those funds remained deferred revenue at year-end and are refundable if SIGA fails to meet contract conditions; the company said revenue recognition awaits satisfaction of those conditions. The filing states existing funds, expected BARDA cash flows, and continuing government grants should support operations for at least 12 months.
Business developments, outlook and risks
- BARDA’s five-year base award was initially described as approximately $435 million. After a competitor protest, the contract was modified: BARDA agreed to purchase 1.7 million courses of ST-246, while SIGA is to contribute 300,000 courses previously manufactured with federal funds. The option to purchase up to 12 million additional courses was removed. Other options cover pediatric and geriatric versions and smallpox prophylaxis.
- FDA’s December 2011 advisory committee supported use of specified animal models, particularly in combination, to provide efficacy evidence under the animal rule. ST-246 remained unapproved; FDA review and approval were not assured. SIGA reported completion of three additional non-human-primate efficacy studies during 2011.
- Other programs, including dengue, Lassa fever and broad-spectrum antivirals, remained in preclinical or early development stages. Management said timelines and completion costs for most programs could not be reasonably estimated and further development depended on funding.
- The principal contingency is PharmAthene litigation. A Delaware Chancery Court ruling awarded PharmAthene 50% of SIGA’s net profits from ST-246 sales after the first $40 million in net profits, for ten years following the first commercial sale, plus one-third of reasonable legal and expert expenses. SIGA accrued approximately $2.0 million for expenses; the amount and timing of any profit-related payments were uncertain, and SIGA said the ruling could materially harm results unless overturned on appeal.
- Key risks include dependence on government procurement and appropriations, contract performance and cost estimates, protests or contract modification, regulatory approval, third-party manufacturing, competition, and uncertain non-government sales. The company also cited reliance on future financing and grants, potential limitations on tax-loss carryforwards, and possible effects of the PharmAthene dispute on deferred-tax asset realizability.
Most important facts for investors to verify
- Current BARDA contract status, delivery milestones, conditions attached to the $41.0 million advance, and the timing and amount of revenue recognition.
- Latest court and appeal developments in the PharmAthene case, including how the profit-sharing award would be calculated and its effect on cash flows and taxes.
- Whether operating cash generation can continue after the one-time advance, and whether government grants or other financing will be available.
- ST-246’s regulatory pathway, animal-rule evidence, manufacturing readiness, and any subsequent FDA decisions.
- The sustainability of the 2011 tax benefit and warrant-related earnings effects; neither represents recurring operating profit.